Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Exelixis Beats Estimates http://www.insidermonkey.com/blog/e...po-logistics-xpo-exelixis-exel-2-more-467597/ Exelixis, Inc. (NASDAQ:EXEL)’s stock is making a bold move today, gaining nearly 7% in the pre-market hours after the company posted better than expected second quarter results. The genomics-based drug discovery company posted a loss of $0.16 per share, above the forecasts of a $0.27 per share loss, while revenue of $36.3 million more than doubled the consensus estimate of $17.96 million. Exelixis expects operating expenses in the range of $250 million-to-$270 million for the full year. Exelixis CEO Michael M. Morrissey said in a statement that his team worked “tirelessly” to bring forward its kidney cancer treatment Cabometyx, and that the company is encouraged by the initial response and developments. A Phase II trial of the drug recently achieved its primary endpoint, as significant improvement was seen in progression-free survival rates in patients with previously untreated advanced renal cell carcinoma. Kenneth Tropin’s Graham Capital Management owns approximately 13.21 million shares of Exelixis, Inc. (NASDAQ:EXEL) as of the end of the first quarter.
Folks if we are lucky to have price drop by manipulation get a loan and buy hand and fist as buyout soon.
BOOM! Big gapper! Exelixis Cancer Treatment Hits Key Milestone According to the release, the FDA determined the company’s supplemental New Drug Application (sNDA) for CaboMetyx (cabozantinib) for patients with previously untreated advanced renal cell carcinoma (RCC) to be sufficiently complete to permit a substantive review. The FDA granted Priority Review of the filing and assigned a Prescription Drug User Fee Act (PDUFA) action date of February 15, 2018.
looks like shorts have become longs with this extraordinary volume on key catalysts, watching for the upgrades & increase price obj.
